Syngene International Limited – FY2025‑26 Board Update

Key Highlights (Board Meeting – 29 Apr 2026)

• Approved audited standalone and consolidated financial statements for Q4 and FY2025‑26.
• Recommended a final dividend of Rs 1.25 per share (record date 26 Jun 2026).
• Appointed S.R. Batliboi & Associates LLP as statutory auditors for the next five years.
• Scheduled the 33rd AGM for 29 July 2026.
• Approved managerial remuneration for Executive Chairperson Kiran Mazumdar‑Shaw.
• Allotted 729,727 shares to the Employees Welfare Trust under the LTIP.

Financial Performance

Standalone figures show a similar pattern: revenue of Rs 34,907 mn, profit of Rs 3,049 mn and EPS diluted of Rs 3.68, down from Rs 11.63 a year earlier.

Drivers of Profit Decline

• Higher operating expenses: employee benefits (+10% YoY) and other expenses rose despite modest revenue growth.
• Exceptional items: a net credit of Rs 229 mn from revised labour‑code gratuity calculations partially offset a Rs 462 mn charge.
• Foreign‑exchange loss of Rs 227 mn (standalone) and Rs 211 mn (consolidated).
• Increased depreciation due to newly capitalised assets (e.g., Rs 70 mn for the Bangalore biologics line).

Cash Flow Snapshot

• Operating cash flow: Rs 9,152 mn (down 22% YoY).
• Investing cash flow: net outflow of Rs 8,604 mn, mainly for PPE purchases and investment‑related activities.
• Financing cash flow: net outflow of Rs 2,150 mn, driven by dividend payment and short‑term borrowing repayments.
• Ending cash: Rs 2,286 mn, indicating a tighter liquidity position.

Strategic Developments

• US biologics manufacturing site (acquired in FY2025) expands single‑use bioreactor capacity to 50,000 L, enhancing large‑molecule services.
• New licence for drug‑substance production line and bonded warehouse in Bangalore adds commercial‑scale biologics capability.
• Employee incentive plan: additional share allotment aligns management interests with shareholders.

Regulatory & Compliance

• Appointment of new auditors ensures continuity under SEBI Listing Regulations.
• Ongoing monitoring of India’s four Labour Codes; a one‑off credit this quarter reflects re‑measurement of gratuity obligations.
• No material legal or compliance issues reported.

Investor Implications

• Dividend: modest payout provides some cash return but is contingent on AGM approval.
• Liquidity: declining cash reserves warrant attention; the company may need to optimise working capital or consider financing.
• Growth prospects: capacity expansions position Syngene to capture higher demand in contract research and biologics manufacturing.
• Risk: margin compression, FX volatility, and regulatory cost impacts could pressure future earnings.

Bottom Line: Syngene shows solid top‑line growth and strategic capacity upgrades, but the sharp profit dip and weaker cash position introduce caution. Investors should watch cost‑control initiatives, the execution of the new US and Indian facilities, and any further guidance on margins.